I start ISO 27001 alignment with a simple rule: link each clinical-app risk to a control, an owner, and a test. ISO/IEC 27001:2022 includes 93 Annex A reference controls, but the goal isn’t to check every box. It’s to protect patient data, prevent harmful changes, and keep care available.
Here’s what I focus on:
- Scope and ownership: Map data flows, clinical risks, and shared duties between healthcare teams and vendors.
- Access: Limit permissions, review accounts, and provide emergency access without delaying care.
- Development and releases: Test code and clinical workflows, protect test data, and plan for rollback.
- Monitoring and recovery: Review logs, verify fixes, coordinate incident response, and test downtime procedures.
- Proof and review: Keep dated test results, track gaps, and use third-party risk assessments to check suppliers - not replace control testing.
<u>ISO 27001 certifies the information security management system, not an individual app.</u> I also treat HIPAA duties separately: ISO alignment alone does not establish HIPAA compliance.
Clinical App ISO 27001 Control Lifecycle
ISO 27001 audits for medical device software
sbb-itb-535baee
Manage Clinical and Administrative Access
Map access controls to A.5.15–A.5.18, privileged access to A.8.2, and authentication to A.8.5. Apply these controls to workforce users, vendors, service accounts, APIs, and remote access - not just the login screen.
Define Roles and Manage Account Access
Least privilege must fit clinical workflow. Base permissions on clinical function, patient assignment, department, and coverage needs. Require individual identities, even at shared workstations. Keep access approval separate from provisioning and review. Nobody should approve their own elevated access.
Assign every service account an owner, narrow permissions, protected credentials, credential rotation requirements, and a retirement process.
| Clinical role | Minimum permissions | Elevated privileges | Review owner | Review evidence |
|---|---|---|---|---|
| Bedside nurse | View and update assigned-patient records; document care; administer medications | Temporary access to cross-unit patients during approved coverage | Nurse manager | Quarterly certification, exception report, access-change ticket |
| Attending physician | View and author records for assigned or treated patients; enter orders | Temporary department-wide access during on-call coverage | Medical department chair | Quarterly review, patient-assignment report |
| Pharmacist | View medication history; verify and reconcile orders | Controlled override of selected medication workflows | Pharmacy director | Quarterly review, override report |
| Health information staff | Manage record-release workflows and demographics | Export or disclosure administration where required | Privacy officer | Monthly export review, approval records |
| Application administrator | Configure the application and manage approved technical settings | Production changes only through privileged access management and approved change requests | System owner or IT security lead | Privileged-session logs, change tickets |
| Vendor support engineer | Narrow, ticket-specific troubleshooting access | Time-limited access to approved tenant, patient records, or function | Vendor owner and system owner | Access approval, session recording, revocation evidence |
Treat provisioning as a governed enterprise risk process, not an IT-only task. Connect HR, credentialing, identity, and application-owner workflows. Before granting access, verify the user’s role, training, and required clinical privileges. When someone changes roles, remove their old permissions unless those permissions are reapproved.
Disable access immediately after involuntary termination or suspected compromise. Set documented removal deadlines for routine departures and contract expirations. Disabling the account alone isn’t enough: revoke active sessions, tokens, API keys, VPN access, and mobile access, too. Each access review should record the reviewer, decisions, exceptions, remediation tickets, and closure dates.
Secure Privileged and Emergency Access
Keep routine and administrator identities separate. Require phishing-resistant MFA, such as FIDO2/WebAuthn, for privileged and other high-risk access where supported. Grant elevated access through an approved, time-limited workflow.
Vendor access requires a named identity, an internal sponsor, application-owner approval, restricted scope, and automatic expiration when the support window ends. This is a critical component of third-party risk management to ensure external access doesn't compromise patient safety. Protect authenticator enrollment and reset processes as tightly as login.
Break-glass access must not wait for approval that delays urgent care. Authenticate the user, record a reason or incident ID, restrict access to the scope needed, and alert the responsible team. Set access to expire automatically or require explicit renewal. Provide a tested emergency path for identity-provider outages, followed by prompt post-event review.
Retain and protect logs of successful and failed authentication, MFA events, privilege changes, vendor activity, and sensitive-record access according to retention policy. Test access during cross-coverage, shift changes, and emergencies. Use these logs as evidence for monitoring, vulnerability response, and incident handling.
Secure Development and Release Changes
Once access is controlled, secure the path from commit to production. Map the clinical-app SDLC to A.8.4 and A.8.25–A.8.32. Give each stage one owner and one approval gate, and retain evidence.
Set Secure Coding and Testing Requirements
Set testable requirements for PHI protection and patient safety, API authorization, input validation, session creation and revocation, encryption, secrets management, safe error messages, and auditability.
Protect the default branch, require multifactor authentication, and require peer review before merging. Maintain a software bill of materials (SBOM) for every production release. Run code, dependency, and secret scans, along with risk-based API and penetration testing.
Block releases with unresolved findings above the release threshold unless an authorized risk acceptance is recorded. Retain reviews, scan results, build logs, artifact hashes, and risk acceptances.
Separate Environments and Protect Test Data
After verifying code quality, keep nonproduction systems isolated from production data and permissions. Separate development, testing, staging, and production credentials, databases, keys, networks, monitoring boundaries, and deployment permissions.
Under A.8.33, favor synthetic or properly de-identified test information. Any exception allowing production data must include justification, owner approval, restricted access, minimum necessary fields, a retention limit, and a deletion-or-return process.
Before release, validate patient matching, medication workflows, result routing, downtime behavior, and interface failures - not just whether the application runs.
Approve Changes and Verify Releases
Once testing is complete, control the release itself. Record the version, interfaces, clinical impact - including PHI and patient safety - downtime needs, approvals, test results, implementation window, rollback criteria, communications, and deployment record. Define change categories by risk, not convenience.
| Change type | Approvals | Testing | Rollback controls | Required evidence |
|---|---|---|---|---|
| Routine | Product or service owner and designated change authority | Automated tests, peer review, security checks appropriate to risk, and regression testing | Tested, versioned rollback or feature-flag plan | Change ticket, review record, test results, deployment log, post-release check |
| High-risk | Clinical owner, security representative, quality or safety lead, and change authority | Threat modeling, expanded integration and clinical validation, vulnerability testing, and documented go/no-go decision | Rehearsed rollback, backup or restore validation, downtime plan, and named decision-maker | Impact assessment, approvals, test evidence, release artifact, communications, rollback record, monitoring results |
| Emergency | On-call clinical and technical authority, with security involvement when feasible | Minimum safe testing before deployment; focused validation after deployment | Immediate rollback or containment procedure, recovery contact list, and increased monitoring | Emergency rationale, timestamped approvals, commands or deployment record, validation results, retrospective review |
Verify that the deployed artifact matches the approved artifact hash. After deployment, check authentication, authorization, clinical workflows, interface messages, audit events, performance, error rates, and data integrity. Record who checked each item, when they checked it, the result, and any corrective action.
Block releases that lack mandatory evidence unless an authorized exception is recorded. Set a firm deadline for emergency-change retrospectives, such as the next business day. Use the review to confirm the rationale, assess unintended effects, update documentation, and decide whether a permanent corrective change is required.
Monitor Threats, Fix Vulnerabilities, and Handle Incidents
Once access and release controls are in place, monitor production activity, fix exposures promptly, and treat abnormal behavior as a possible incident.
Collect and Review Application Logs
Map logging to A.8.15, monitoring to A.8.16, and clock synchronization to A.8.17. Log authentication, privilege changes, PHI access, administrative changes, API failures, suspicious automation, malware indicators, and alert outcomes. Each record should include the event ID, actor or service identity, source, action, result, target, and correlation ID.
Sync clocks to an approved time source. Store UTC timestamps and document how to convert them to local time. Keep unnecessary PHI, passwords, tokens, and keys out of logs.
Send logs to access-controlled, tamper-evident or immutable storage, and trigger alerts if logging stops or someone tampers with it. Define retention and disposal rules, alert thresholds, and review frequency. Send urgent alerts to security operations, PHI-access reviews to privacy officers, and unexpected order, result, or documentation failures to application owners.
HIPAA does not set one universal audit-log retention period. Document the organizational, contractual, state, and legal requirements that apply. Extend retention when logs are needed as incident evidence.[4][5][7]
Use logs first to detect unapproved changes, failed controls, and patient-safety risks.
Find, Fix, and Retest Vulnerabilities
Under A.8.8, connect asset and dependency inventories to scans, configuration reviews, penetration tests, and third-party vendor risk assessments. Set fix deadlines based on exploitability, internet exposure, PHI impact, and patient-care risk - not severity scores alone. This approach is critical when managing threats to patient care across the digital ecosystem.
Act immediately when exploitation is active or patient risk is urgent. Validate patches against clinical workflows and interfaces. If a fix must wait, document compensating controls, an accountable owner, and an expiration date.
Close findings only after retesting confirms the fix. Retain the affected version, retest result, and closure approval.[8]
When exploitation is active or care is at risk, shift from remediation to incident handling.
Coordinate Incident Response and Care Continuity
Map incident preparation through lessons learned to A.5.24–A.5.28. Set one reporting path and name contacts across security, clinical, privacy, legal, and vendor teams. Escalate threats to medication administration, diagnosis, or emergency care immediately - even before confirmation. When practical, preserve logs and volatile evidence before rebuilding, and record the chain of custody.
Keep incident handling separate from the HIPAA breach determination. Treat ransomware-encrypted ePHI as a breach unless the required assessment shows a low probability of compromise.[9][10] HHS requires applicable breach notifications without unreasonable delay and no later than 60 calendar days after discovery.[3][5][6] State or contractual deadlines may be shorter.
| Event | Initial owner | Escalation threshold | Required evidence | Clinical continuity action |
|---|---|---|---|---|
| Repeated authentication failures or suspected account takeover | Security operations and identity team | Confirmed compromise, privileged account involvement, or unusual PHI access | Identity logs, MFA events, session records, PHI-access history | Disable compromised access or require stronger authentication; use approved alternate access for care |
| Unusual PHI export or disclosure | Privacy/security team | Unapproved recipient, bulk export, or potential unsecured-PHI exposure | Export records, recipient details, affected data | Restrict exports while preserving access to records needed for care |
| Malicious configuration or code change | Application owner and security operations | Unapproved production change, integrity failure, or clinical workflow disruption | Deployment logs, approvals, hashes, administrator activity | Roll back or isolate the change; switch to downtime workflow if unsafe |
| Ransomware or destructive malware | Incident commander and infrastructure team | Encryption, destructive activity, or spread toward clinical systems | Endpoint telemetry, network flows, memory or disk evidence | Segment affected systems; switch to downtime workflow and prioritize life-sustaining services |
| Interface or integration outage | Interface owner and clinical operations | Lost results, orders, monitoring data, or prolonged message backlog | Queue metrics, delivery acknowledgments, error logs | Use manual reconciliation; replay messages only after clinical validation |
For A.5.30, connect downtime procedures to clinical recovery priorities, recovery time and recovery point objectives, backups, alternate communications, and vendor responsibilities. Test restoration and rehearse patient identification, medication ordering, results review, and documentation during outages.
Before restoring clinical service, require security confirmation that containment is complete and integrity is intact. Also require clinical validation of access, data completeness, interfaces, and duplicate-order prevention. Record actual recovery times, failed checks, corrective-action owners, and retest results.[8]
Maintain Evidence and Review Risks
After implementation, use evidence and regular reviews to confirm that each mapped control still works. Keep an evidence register for each SoA control, linking its control ID to the clinical application, owner, evidence location, review date, exceptions, and risk treatment decision. Use the same control IDs and owners established in the control record.
Include evidence for access, logging, changes, testing, remediation, incidents, training, and suppliers. A document’s existence isn’t enough. The evidence should show who reviewed it, what the review covered, what failed, and who approved it.
Measure Control Effectiveness
Use the register to measure whether controls still work. Track on-time privileged-access reviews, timely deprovisioning, release-gate compliance, remediation against risk-based deadlines, completed log reviews, and incident detection and response times.
For each metric, define its owner, source, calculation, review frequency, target, and escalation threshold. Track results by patient-safety impact, PHI exposure, and downtime risk. Set targets around clinical dependencies, rather than applying one deadline to every application.
Meet monthly with application owners, security, clinical stakeholders, and suppliers to review evidence, exceptions, and remediation. Record gaps, owners, due dates, and treatment decisions. Reassess after major releases, new integrations, supplier changes, or changes to clinical workflows. Every exception needs compensating controls, an accountable approver, an expiration date, and a reassessment trigger.
Internal audits should sample actual control activity. Management reviews should examine trends, major risks, and resource needs. Link each corrective action to the original finding, root cause, and verification evidence. Close findings only after verification evidence confirms remediation. If verification or reassessment reveals remaining gaps, update the risk treatment plan and control coverage.
Coordinate Healthcare Risk Assessments With Censinet
For third-party and enterprise assessments, Censinet RiskOps™ can help coordinate assessments, organize supplier evidence, track remediation, and support benchmarking and collaborative risk management across clinical applications, PHI, suppliers, and integrations.
Validate the scope, coverage period, and exceptions. Benchmarking can inform a review, but it doesn’t validate a control. The platform supports assessment coordination; it does not replace control implementation or evidence validation.
Conclusion: Keep Controls Aligned With Clinical Risks
Map each clinical-app risk to an ISO/IEC 27001 control. Assign an owner, test the control, and keep evidence that it works. Focus on patient safety, confidentiality, integrity, and availability, and fix any gaps promptly.[11][12]
Policies state intent; evidence from day-to-day work shows whether controls perform as intended.
ISO/IEC 27001 alignment does not establish HIPAA compliance, and application safeguards do not equal certification.[1][2] Certification depends on the defined ISMS scope and conformity, backed by evidence - not policy language alone.[13]
FAQs
Which ISO 27001 controls should we prioritize first?
Focus on ISO 27001 controls that protect patient data, keep systems available, and meet HIPAA requirements. Start with a system inventory and gap analysis to identify major vulnerabilities.
Use your organization’s risks to set priorities for access management, encryption, and audit logging. Rather than implementing every control at once, address risks based on their potential impact on patient care, safety, and protected health information (PHI) exposure.
How do we divide control responsibilities with vendors?
Make vendor responsibilities legally binding. Contracts should spell out requirements for data protection, security controls, and incident reporting, including Business Associate Agreements (BAAs) for protected health information (PHI).
Apply these requirements throughout the vendor relationship - from pre-contract evaluation and onboarding to day-to-day work and offboarding. Align each vendor’s incident response plan with yours so escalation paths, communication protocols, and reporting obligations are clear.
Censinet RiskOps can automate workflows, simplify risk assessments, and track how vendor controls align with ISO 27001 requirements.
How can we test security controls without disrupting care?
Take a risk-based approach to testing. Schedule intensive tests during off-peak hours, use agentless scanning, and limit bandwidth usage to protect clinical application performance. Keep emergency stop procedures ready so testing can be halted if it affects clinical systems.
Use synthetic or masked data in development and deployment environments, along with zero-downtime deployment methods. Involve clinical staff so security measures fit their workflows, and make risk assessments part of routine technology rollouts.
